Shawver Laura — SEC Form 4 filings
SEC reporting owner CIK 1551891. 9 Form 4 filings on record with FilingPulse; latest filed 2026-06-26.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-06-05 to 2026-06-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 9 legs across 5 filings — 400,002 shares, $5,034,901 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 28.
- Largest priced transaction: sale of 96,343 shares @ $13.55 ($1,305,823) in ARS Pharmaceuticals, Inc., filed 2024-12-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | Director | 8 | — | 9 legs · 400,002 sh · $5,034,901 | 27 |
| Relay Therapeutics, Inc. (RLAY) | Director | 1 | — | — | 1 |
Form 4 filings — Shawver Laura
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-26 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-04-08 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 22,509 @ $4.85 · Option exercise (M): 27,493 @ $4.85 · Sale (S): 50,002 @ $12.30 · Option exercise (M): 22,509 (derivative) @ $0 · Option exercise (M): 27,493 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 400 @ $4.85 · Sale (S): 400 @ $11 · Option exercise (M): 49,600 @ $4.85 · Sale (S): 49,600 @ $11.21 · Option exercise (M): 400 (derivative) @ $0 · Option exercise (M): 49,600 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 9,064 @ $3.15 · Option exercise (M): 40,936 @ $4.85 · Sale (S): 50,000 @ $12.31 · Option exercise (M): 9,064 (derivative) @ $0 · Option exercise (M): 40,936 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 50,000 @ $3.15 · Sale (S): 50,000 @ $11.10 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 67,616 @ $1.27 · Option exercise (M): 29,628 @ $1.27 · Sale (S): 96,343 @ $13.55 · Sale (S): 901 @ $14.34 · Option exercise (M): 25,606 @ $1.27 · Option exercise (M): 62,378 @ $3.15 · +8 more | EDGAR |
| 2024-06-24 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Relay Therapeutics, Inc. (RLAY) | Grant/award (A): 102,225 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1551891 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →